Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
krill oil liposomes
- Development stage
- Preclinical
- Lead developer
- Ajou University
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
Krill oil liposomes are a lipid-based nanoparticle drug delivery system designed for the oral treatment of inflammatory bowel disease (IBD). This formulation incorporates krill oil—which is naturally rich in omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) and phosphatidylcholine—into a stable liposomal bilayer. Unlike liposomes made with free omega-3 fatty acids, krill oil liposomes maintain colloidal stability and resist membrane fusion in gastrointestinal conditions. The system acts by suppressing the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), and by physically reinforcing the intestinal mucosal barrier. It has been investigated primarily as a vehicle for the corticosteroid budesonide to enhance local delivery to inflamed colonic tissue and reduce systemic endotoxin levels.
- Other names
- Omega-3-incorporated PC nanoparticlesOmega3-incorporated PC nanoparticlesOmega 3-incorporated PC nanoparticleskrill oil-incorporated liposomes
02
Targets
NF-κBIL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on krill oil liposomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on krill oil liposomes.